<< Back To Search

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT06208150
Age 18 +
Sex Both
Phase Phase 3
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
  • The treatment involves a unique combination of drugs that target different aspects of the disease.
  • Participants will receive either the new treatment or standard care, allowing researchers to compare the effectiveness of both.
  • The study aims to assess how well the new treatment works in reducing symptoms and improving quality of life.
  • Researchers are also looking at the safety of the new treatment, monitoring any side effects that may occur.
  • This study is notable for its focus on personalized medicine, tailoring treatment based on individual patient characteristics.
  • Patients will be closely monitored throughout the study, with regular check-ups to track their progress.
  • The study includes a diverse group of participants, which may help in understanding how different populations respond to the treatment.
Overall, this clinical study represents an important step in finding more effective treatment options for patients, with the hope of improving their health and well-being.
Third Opinion AI Generated Synopsis

Trial Summary
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: